Similar trends were observed for changes in total cholesterol .
Implication sGiven the available data , the addition of ezetimibe to ongoing simvastatin , atorvastatin , or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose
Purpose While statins are used as first-line treatments for high-risk patients with hypercholesterolemia , statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol ( LDL-C ) levels .
Second-line treatment options include up-titration of statin dose , switching to a more potent statin , or combination therapy , e.g. , with ezetimibe .
The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin , atorvastatin , or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease ( CVD ) and who had been previously treated with a statin .
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
The present multicenter , 6-week , r and omized , double-blind , parallel-group , clinical trial evaluated the safety and efficacy of ezetimibe ( 10 mg ) added to stable rosuvastatin therapy versus up-titration of rosuvastatin from 5 to 10 mg or from 10 to 20 mg . The study population included 440 subjects at moderately high/high risk of coronary heart disease with low-density lipoprotein ( LDL ) cholesterol levels higher than the National Cholesterol Education Program Adult Treatment Panel III recommendations ( < 100 mg/dl for moderately high/high-risk subjects without atherosclerotic vascular disease or < 70 mg/dl for high-risk subjects with atherosclerotic vascular disease ) . Pooled data demonstrated that ezetimibe added to stable rosuvastatin 5 mg or 10 mg reduced LDL cholesterol by 21 % . In contrast , doubling rosuvastatin to 10 mg or 20 mg reduced LDL cholesterol by 5.7 % ( between-group difference of 15.2 % , p < 0.001 ) . Individually , ezetimibe plus rosuvastatin 5 mg reduced LDL cholesterol more than did rosuvastatin 10 mg ( 12.3 % difference , p < 0.001 ) , and ezetimibe plus rosuvastatin 10 mg reduced LDL cholesterol more than did rosuvastatin 20 mg ( 17.5 % difference , p < 0.001 ) . Compared to rosuvastatin up-titration , ezetimibe add-on achieved significantly greater attainment of LDL cholesterol levels of < 70 or < 100 mg/dl ( 59.4 % vs 30.9 % , p < 0.001 ) , and < 70 mg/dl in all subjects ( 43.8 % vs 17.5 % , p < 0.001 ) ; produced significantly greater reductions in total cholesterol , non-high-density lipoprotein cholesterol , and apolipoprotein B ( p < 0.001 ) ; and result ed in similar effects on other lipid parameters . Adverse experiences were generally comparable among the groups . In conclusion , compared to up-titration doubling of the rosuvastatin dose , ezetimibe 10 mg added to stable rosuvastatin 5 mg or 10 mg produced greater improvements in many lipid parameters and achieved greater attainment of the National Cholesterol Education Program Adult Treatment Panel III recommended LDL cholesterol targets in subjects with elevated LDL cholesterol and at moderately high/high coronary heart disease risk
Similar trends were observed for changes in total cholesterol .
Implication sGiven the available data , the addition of ezetimibe to ongoing simvastatin , atorvastatin , or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose
Purpose While statins are used as first-line treatments for high-risk patients with hypercholesterolemia , statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol ( LDL-C ) levels .
Second-line treatment options include up-titration of statin dose , switching to a more potent statin , or combination therapy , e.g. , with ezetimibe .
The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin , atorvastatin , or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease ( CVD ) and who had been previously treated with a statin .